Physician profile
Ronald E Mason
NPI 1124088430
$3,378.31
in general payments reported to CMS, 2019-2025
21 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.87 · 2020: $180 · 2021: $285 · 2022: $561 · 2023: $660 · 2024: $773 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246 · Education: $29.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.96 |
| Education | $29.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $566.92 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $546.56 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $426.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.94 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Regeneron Healthcare Solutions, INC. | $265.36 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $263.13 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $209.28 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $162.93 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $85.64 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $84.65 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $81.81 | 2021-2023 | |
| Genzyme Corporation | $70.89 | 2024-2025 | |
| Celltrion USA INC. | $58.50 | 2024 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $51.30 | 2025 | Rezdiffra |
| Lilly USA, LLC | $48.22 | 2024 | Omvoh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $33.03 | 2023 | Suflave |
| Phathom Pharmaceuticals, INC. | $30.75 | 2025 | Voquezna |
| Organon LLC | $25.89 | 2024 | |
| Novo Nordisk INC | $22.95 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $18.85 | 2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $16.76 | 2025 | Oxlumo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.